Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Since Rallybio launched in 2018, the company has been laser-focused on the development of “transformative therapeutics” for patients suffering from rare and ultra-rare diseases.
Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics...
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
PCN-101 was recently awarded Investigational New Drug (IND) status by the U.S. Food and Drug Administration. It’s a for treating the patients with treatment resistant depression.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.
Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.
One hundred percent of test serum samples showed neutralization of the delta variant, and more than ninety percent of serum samples showed neutralization of the Omicron variant.
BioSpace takes a look at the presentations made by Amgen, GSK and 2sevent bio at the all-virtual J.P. Morgan Conference.
Daiichi wants to maximize its investment in three antibody-drug conjugates, which the company has positioned as one of the strategic pillars of its 5-year Business Plan.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
The FDA informed Johnson & Johnson that adverse-event reports indicated a possible increased risk of immune thrombocytopenia within 42 days after vaccination with their COVID-19 vaccine.
Pfizer is cutting its sales staff as physicians and healthcare facilities prefer fewer face-to-face interactions with vendors due to the COVID-19 pandemic.
PRESS RELEASES
• ASCO 2026: 2.5-Year Overall Survival Data • Jefferies Healthcare Conference: Partnering & Investor meetings • BIO International Convention: Panel Participation • MIB Agents Factor Osteosarcoma Conference: Data Presentation
The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia’s Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025
Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT
• MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSanteTM. • Based on infield grower data, the mustard-derived TerraSanteTM biofertility product has been shown to improve crop yields, soil, and potentially the soil microbiome health for nutrient/water use efficiencies.
· Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of MetrioPharm AG. · With more than 800 peer-reviewed publications and various prestigious awards, Prof. Braun is internationally recognized as a leading expert in the field of modern clinical and academic rheumatology.